Puma Biotechnology Company Profile (NYSE:PBYI)

About Puma Biotechnology (NYSE:PBYI)

Puma Biotechnology logoPuma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NYSE:PBYI
  • CUSIP: N/A
  • Web: www.pumabiotechnology.com/
Capitalization:
  • Market Cap: $3.49 billion
  • Outstanding Shares: 36,966,000
Average Prices:
  • 50 Day Moving Avg: $84.95
  • 200 Day Moving Avg: $50.35
  • 52 Week Range: $28.35 - $97.15
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -22.67
  • P/E Growth: 0.02
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $4.53 per share
  • Price / Book: 20.82
Profitability:
  • EBIDTA: ($277,330,000.00)
  • Return on Equity: -154.96%
  • Return on Assets: -124.52%
Debt:
  • Current Ratio: 3.12%
  • Quick Ratio: 3.12%
Misc:
  • Average Volume: 1.68 million shs.
  • Beta: 0.35
  • Short Ratio: 4.79
 
Frequently Asked Questions for Puma Biotechnology (NYSE:PBYI)

What is Puma Biotechnology's stock symbol?

Puma Biotechnology trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBYI."

How were Puma Biotechnology's earnings last quarter?

Puma Biotechnology Inc (NYSE:PBYI) posted its quarterly earnings data on Wednesday, May, 10th. The company reported ($1.97) EPS for the quarter, beating analysts' consensus estimates of ($2.06) by $0.09. View Puma Biotechnology's Earnings History.

Where is Puma Biotechnology's stock going? Where will Puma Biotechnology's stock price be in 2017?

8 brokerages have issued 12 month target prices for Puma Biotechnology's shares. Their predictions range from $88.00 to $125.00. On average, they anticipate Puma Biotechnology's stock price to reach $111.13 in the next twelve months. View Analyst Ratings for Puma Biotechnology.

Who are some of Puma Biotechnology's key competitors?

Who are Puma Biotechnology's key executives?

Puma Biotechnology's management team includes the folowing people:

  • Alan H. Auerbach, Chairman of the Board, President, Chief Executive Officer
  • Charles R. Eyler, Senior Vice President - Finance and Administration, Treasurer
  • Richard P. Bryce, Senior Vice President - Clinical Research and Development.
  • Steven Lo, Chief Commercial Officer
  • Jay M. Moyes, Independent Director
  • Adrian M. Senderowicz M.D., Independent Director
  • Troy E. Wilson Ph.D. J.D., Independent Director
  • Frank E. Zavrl, Independent Director

Who owns Puma Biotechnology stock?

Puma Biotechnology's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Franklin Street Advisors Inc. NC (0.06%), Capital Impact Advisors LLC (0.05%), Bank of Montreal Can (0.01%), Creative Planning (0.01%) and Fox Run Management L.L.C. (0.01%). Company insiders that own Puma Biotechnology stock include Adage Capital Partners Gp, LL, Alan H Auerbach, Richard Paul Bryce and Robert Charnas. View Institutional Ownership Trends for Puma Biotechnology.

Who sold Puma Biotechnology stock? Who is selling Puma Biotechnology stock?

Puma Biotechnology's stock was sold by a variety of institutional investors in the last quarter, including Capital Impact Advisors LLC and Franklin Street Advisors Inc. NC. Company insiders that have sold Puma Biotechnology stock in the last year include Adage Capital Partners Gp, LL, Alan H Auerbach, Richard Paul Bryce and Robert Charnas. View Insider Buying and Selling for Puma Biotechnology.

Who bought Puma Biotechnology stock? Who is buying Puma Biotechnology stock?

Puma Biotechnology's stock was bought by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C., Creative Planning and Bank of Montreal Can. View Insider Buying and Selling for Puma Biotechnology.

How do I buy Puma Biotechnology stock?

Shares of Puma Biotechnology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Puma Biotechnology's stock price today?

One share of Puma Biotechnology stock can currently be purchased for approximately $94.30.


MarketBeat Community Rating for Puma Biotechnology (NYSE PBYI)
Community Ranking:  2.9 out of 5 ( )
Outperform Votes:  234 (Vote Outperform)
Underperform Votes:  168 (Vote Underperform)
Total Votes:  402
MarketBeat's community ratings are surveys of what our community members think about Puma Biotechnology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Puma Biotechnology (NYSE:PBYI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $111.13 (17.84% upside)

Analysts' Ratings History for Puma Biotechnology (NYSE:PBYI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/22/2017Cowen and CompanyReiterated RatingOutperform$91.00 -> $120.00N/AView Rating Details
7/21/2017Bank of America CorporationReiterated RatingBuy$100.00 -> $117.00LowView Rating Details
7/19/2017Leerink SwannReiterated RatingOutperform$115.00 -> $125.00MediumView Rating Details
7/17/2017Royal Bank Of CanadaSet Price TargetHold$88.00MediumView Rating Details
7/18/2017J P Morgan Chase & CoReiterated RatingBuyMediumView Rating Details
7/18/2017Citigroup Inc.Reiterated RatingBuy$114.00MediumView Rating Details
7/18/2017Stifel NicolausReiterated RatingBuy$105.00 -> $118.00MediumView Rating Details
7/18/2017Credit Suisse GroupReiterated RatingOutperform$90.00 -> $118.00HighView Rating Details
1/5/2016Berenberg BankUpgradeHold -> BuyN/AView Rating Details
(Data available from 7/23/2015 forward)

Earnings

Earnings History for Puma Biotechnology (NYSE:PBYI)
Earnings by Quarter for Puma Biotechnology (NYSE:PBYI)
Earnings History by Quarter for Puma Biotechnology (NYSE PBYI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($2.06)($1.97)ViewN/AView Earnings Details
3/1/2017Q4($1.92)($2.04)ViewN/AView Earnings Details
5/10/2016Q1($1.99)($1.28)ViewN/AView Earnings Details
2/29/2016Q4($1.95)($1.23)ViewN/AView Earnings Details
11/9/2015Q3($1.84)($1.87)ViewN/AView Earnings Details
8/10/2015Q2($1.55)($1.13)ViewN/AView Earnings Details
5/11/2015Q1($1.25)($1.02)ViewN/AView Earnings Details
3/2/2015($1.15)($1.59)ViewN/AView Earnings Details
11/10/2014($1.27)($1.19)ViewN/AView Earnings Details
8/11/2014Q214($0.66)($1.05)ViewN/AView Earnings Details
5/12/2014($0.48)($0.67)ViewN/AView Earnings Details
3/3/2014Q413($0.49)($0.46)ViewN/AView Earnings Details
4/1/2013Q413($0.70)($0.25)ViewN/AView Earnings Details
11/14/2012Q312($1.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Puma Biotechnology (NYSE:PBYI)
Current Year EPS Consensus Estimate: $-8.43 EPS
Next Year EPS Consensus Estimate: $-4.16 EPS

Dividends

Dividend History for Puma Biotechnology (NYSE:PBYI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Puma Biotechnology (NYSE:PBYI)
Insider Ownership Percentage: 22.70%
Institutional Ownership Percentage: 80.98%
Insider Trades by Quarter for Puma Biotechnology (NYSE:PBYI)
Institutional Ownership by Quarter for Puma Biotechnology (NYSE:PBYI)
Insider Trades by Quarter for Puma Biotechnology (NYSE:PBYI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/3/2017Richard Paul BryceSVPSell5,000$87.10$435,500.00View SEC Filing  
6/12/2017Adage Capital Partners Gp, L.LMajor ShareholderSell247,260$80.32$19,859,923.20View SEC Filing  
6/5/2017Adage Capital Partners Gp, L.LMajor ShareholderSell507,128$87.84$44,546,123.52View SEC Filing  
5/26/2017Adage Capital Partners Gp, L.LMajor ShareholderSell1,235,700$75.38$93,147,066.00View SEC Filing  
2/1/2017Robert CharnasInsiderSell3,008$31.83$95,744.64View SEC Filing  
1/20/2017Alan H AuerbachInsiderSell10,202$33.24$339,114.48View SEC Filing  
1/20/2017Richard Paul BryceSVPSell2,293$33.24$76,219.32View SEC Filing  
7/6/2015Richard Paul BryceSVPSell3,000$110.03$330,090.00View SEC Filing  
11/8/2013Adage Capital Partners Gp Llcmajor shareholderBuy22,549$38.92$877,607.08View SEC Filing  
11/5/2013Adage Capital Partners Gp Llcmajor shareholderBuy280,700$39.60$11,115,720.00View SEC Filing  
10/9/2013Adage Capital Partners Gp Llcmajor shareholderBuy140,900$40.44$5,697,996.00View SEC Filing  
12/18/2012Adage Capital Partners Gp LlcMajor ShareholderBuy29,560$19.00$561,640.00View SEC Filing  
12/12/2012Adage Capital Partners Gp LlcMajor ShareholderBuy30,400$19.00$577,600.00View SEC Filing  
12/11/2012Adage Capital Partners Gp LlcMajor ShareholderBuy140,040$18.98$2,657,959.20View SEC Filing  
10/24/2012Thomas MalleyDirectorBuy10,000$16.00$160,000.00View SEC Filing  
10/18/2012Adage Capital Partners Gp LlcMajor ShareholderBuy610,000$16.00$9,760,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Puma Biotechnology (NYSE:PBYI)
Latest Headlines for Puma Biotechnology (NYSE:PBYI)
Source:
DateHeadline
americanbankingnews.com logoCowen and Company Reaffirms "Outperform" Rating for Puma Biotechnology Inc (NYSE:PBYI)
www.americanbankingnews.com - July 22 at 10:56 AM
americanbankingnews.com logoPuma Biotechnology Inc (NYSE:PBYI) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - July 21 at 12:54 PM
americanbankingnews.com logoBank of America Corporation Reaffirms "Buy" Rating for Puma Biotechnology Inc (NYSE:PBYI)
www.americanbankingnews.com - July 21 at 9:30 AM
americanbankingnews.com logoPuma Biotechnology Target of Unusually High Options Trading (PBYI)
www.americanbankingnews.com - July 21 at 7:18 AM
benzinga.com logoPuma Biotechnology Boosted After FDA Approves Breast Cancer Therapy - Benzinga
www.benzinga.com - July 19 at 3:43 PM
americanbankingnews.com logoPuma Biotechnology Inc (NYSE:PBYI) Rating Reiterated by Leerink Swann
www.americanbankingnews.com - July 19 at 10:32 AM
benzinga.com logoPuma Biotechnology Boosted After FDA Approves Breast Cancer Therapy
www.benzinga.com - July 19 at 1:56 AM
finance.yahoo.com logoPuma Biotech Wins Big on FDA Approval of Breast Cancer Treatment
finance.yahoo.com - July 19 at 1:56 AM
finance.yahoo.com logoPuma Biotechnology Inc (PBYI) Drug Nerlynx Set To Hit The Market; J.P. Morgan Chimes In
finance.yahoo.com - July 19 at 1:56 AM
finance.yahoo.com logoCould This Biotech Stir Takeover Interest After Cancer Drug Approval?
finance.yahoo.com - July 19 at 1:56 AM
finance.yahoo.com logoPuma's (PBYI) Breast Cancer Drug Neratinib Gets FDA Approval
finance.yahoo.com - July 19 at 1:56 AM
finance.yahoo.com logoDoes Puma Biotechnology's Approval Make It Worth More?
finance.yahoo.com - July 19 at 1:56 AM
americanbankingnews.com logoPuma Biotechnology Inc (NYSE:PBYI) Rating Reiterated by J P Morgan Chase & Co
www.americanbankingnews.com - July 18 at 4:17 PM
americanbankingnews.com logoPuma Biotechnology Inc (NYSE:PBYI) Given a $88.00 Price Target at Royal Bank Of Canada
www.americanbankingnews.com - July 18 at 3:40 PM
americanbankingnews.com logoPuma Biotechnology Inc (PBYI) Earns Buy Rating from Stifel Nicolaus
www.americanbankingnews.com - July 18 at 1:09 PM
nasdaq.com logoUS FDA approves Puma Biotech's breast cancer treatment - Nasdaq
www.nasdaq.com - July 18 at 7:07 AM
streetinsider.com logoPuma Biotech's (PBYI) Neratinib Receives FDA Approval for Extended Adjuvant Treatment of Early Stage HER2 ... - StreetInsider.com
www.streetinsider.com - July 18 at 7:07 AM
marketwatch.com logoPuma jumps after FDA approval of breast-cancer treatment - MarketWatch
www.marketwatch.com - July 18 at 7:07 AM
finance.yahoo.com logoU.S. Food and Drug Administration Approves Puma’s NERLYNX™ (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
finance.yahoo.com - July 18 at 7:07 AM
finance.yahoo.com logoPuma jumps after FDA approval of breast-cancer treatment
finance.yahoo.com - July 18 at 7:07 AM
americanbankingnews.com logoPuma Biotechnology Inc (PBYI) SVP Sells $435,500.00 in Stock
www.americanbankingnews.com - July 14 at 8:24 PM
americanbankingnews.com logoPuma Biotechnology Inc (NYSE:PBYI) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - July 11 at 3:38 PM
finance.yahoo.com logoPuma Biotech Is up 181% This Year; Here's Why It Can Still Go Higher
finance.yahoo.com - July 11 at 6:32 AM
americanbankingnews.com logoPuma Biotechnology Inc (PBYI) Earns "Outperform" Rating from Leerink Swann
www.americanbankingnews.com - July 11 at 12:10 AM
americanbankingnews.com logo-$2.13 Earnings Per Share Expected for Puma Biotechnology Inc (PBYI) This Quarter
www.americanbankingnews.com - July 10 at 10:22 PM
americanbankingnews.com logoPuma Biotechnology's (NYSE:PBYI) Buy Rating Reaffirmed at Stifel Nicolaus
www.americanbankingnews.com - July 10 at 10:38 AM
seekingalpha.com logoPuma's FDA Decider And Semaglutide's Head-To-Head Battle - Seeking Alpha
seekingalpha.com - July 8 at 1:25 PM
streetinsider.com logoPuma Biotech (PBYI) Reports Completion of Targeted Enrollment in Neratinib Phase III Metastatic Breast Cancer Trial - StreetInsider.com
www.streetinsider.com - July 8 at 1:25 PM
finance.yahoo.com logoPuma (PBYI) Ends Patient Enrollment in Phase III Cancer Trial
finance.yahoo.com - July 8 at 1:25 PM
rttnews.com logoBMY's Orencia Scores Another FDA Nod, Janssen Ends Deal With CAPR, PBYI On Track
www.rttnews.com - July 7 at 8:00 AM
finance.yahoo.com logoPuma Biotechnology Completes Targeted Enrollment in Neratinib Phase III Metastatic Breast Cancer Trial
finance.yahoo.com - July 7 at 8:00 AM
seekingalpha.com logoPuma Stalks Up - Seeking Alpha
seekingalpha.com - July 5 at 9:27 AM
finance.yahoo.com logoAre Options Traders Betting on a Big Move in Puma Biotechnology (PBYI) Stock?
finance.yahoo.com - July 4 at 5:38 AM
americanbankingnews.com logoCitigroup Inc. Reiterates "Buy" Rating for Puma Biotechnology Inc (PBYI)
www.americanbankingnews.com - June 30 at 7:12 PM
americanbankingnews.com logoPuma Biotechnology Inc (PBYI) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - June 26 at 12:51 PM
finance.yahoo.com logoPuma (PBYI) Stock Surges as Neratinib Nears FDA Approval
finance.yahoo.com - June 16 at 8:44 AM
americanbankingnews.com logoPuma Biotechnology Inc (PBYI) Expected to Post Earnings of -$2.13 Per Share
www.americanbankingnews.com - June 14 at 10:34 PM
americanbankingnews.com logoPuma Biotechnology Inc (PBYI) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - June 14 at 7:34 AM
finance.yahoo.com logoThe Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Puma Biotechnology, Inc. Shareholders and a Lead Plaintiff Deadline of July 7, 2017
finance.yahoo.com - June 13 at 7:15 PM
americanbankingnews.com logoAdage Capital Partners Gp, L.L Sells 247,260 Shares of Puma Biotechnology Inc (PBYI) Stock
www.americanbankingnews.com - June 12 at 7:14 PM
finance.yahoo.com logoThe Klein Law Firm Announces a Class Action Filed on Behalf of Puma Biotechnology, Inc. Shareholders and a Lead Plaintiff Deadline of July 7, 2017
finance.yahoo.com - June 12 at 6:48 PM
americanbankingnews.com logoPuma Biotechnology Inc (PBYI) PT Raised to $88.00
www.americanbankingnews.com - June 11 at 3:58 PM
americanbankingnews.com logoPuma Biotechnology's (PBYI) Overweight Rating Reiterated at JPMorgan Chase & Co.
www.americanbankingnews.com - June 11 at 12:46 PM
seekingalpha.com logoPuma Biotechnology (PBYI) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 9 at 1:02 AM
businesswire.com logoPBYI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Puma ... - Business Wire (press release)
www.businesswire.com - June 8 at 8:01 PM
finance.yahoo.com logoPBYI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Puma Biotechnology, Inc. and a Lead Plaintiff Deadline of July 7, 2017
finance.yahoo.com - June 8 at 8:01 PM
americanbankingnews.com logoPuma Biotechnology Inc (PBYI) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - June 8 at 1:36 PM
seekingalpha.com logoPuma Biotechnology's Neratinib Set To Target Extended Adjuvant Opportunity - Seeking Alpha
seekingalpha.com - June 8 at 12:01 AM
americanbankingnews.com logoPuma Biotechnology Inc (PBYI) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - June 7 at 9:44 AM
benzinga.com logo3 Takeaways From Monday's ASCO Meetings: Puma Biotech, Incyte, Celgene - Benzinga
www.benzinga.com - June 7 at 12:57 AM

Social

Chart

Puma Biotechnology (PBYI) Chart for Sunday, July, 23, 2017

This page was last updated on 7/23/2017 by MarketBeat.com Staff